Tenax Therapeutics Overview
- Year Founded
-
1967
- Status
-
Public
- Employees
-
16
- Stock Symbol
-
TENX
- Investments
-
4
- Share Price
-
$1.62
- (As of Friday Closing)
Tenax Therapeutics General Information
Description
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Contact Information
Website
www.tenaxthera.comCorporate Office
- 101 Glen Lennox Drive
- Suite 300
- Chapel Hill, NC 27517
- United States
Corporate Office
- 101 Glen Lennox Drive
- Suite 300
- Chapel Hill, NC 27517
- United States
Tenax Therapeutics Timeline
Tenax Therapeutics Stock Performance
As of 13-Nov-2026, Tenax Therapeutics’s stock price is $1.62. Its current market cap is $73.8M with 45.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.62 | $1.61 | $1.31 - $19.40 | $73.8M | 45.5M | 3.76M | -$1.39 |
Tenax Therapeutics Financials Summary
As of 30-Sep-2026, Tenax Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (47,245) | (23,260) | (77,210) | (4,414) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (69,559) | (56,418) | (19,493) | (8,163) |
| Net Income | (65,763) | (52,599) | (17,602) | (7,711) |
| Total Assets | 117,014 | 104,227 | 96,686 | 11,685 |
| Total Debt | 0 | 0 | 0 | 501 |
Tenax Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tenax Therapeutics Comparisons
Industry
Financing
Details
Tenax Therapeutics Competitors (70)
One of Tenax Therapeutics’s 70 competitors is viDA Therapeutics, a Venture Capital-Backed company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| viDA Therapeutics | Venture Capital-Backed | Vancouver, Canada | ||||
| XyloCor Therapeutics | Venture Capital-Backed | King of Prussia, PA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Vivus | Corporate Backed or Acquired | Campbell, CA | ||||
| Regenerx | Formerly VC-backed | Rockville, MD |
Tenax Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tenax Therapeutics Patents
Tenax Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3240614-A1 | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | Pending | 31-Dec-2021 | ||
| EP-4456897-A1 | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | Pending | 31-Dec-2021 | ||
| EP-4456897-A4 | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | Pending | 31-Dec-2021 | ||
| US-20250064799-A1 | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | Pending | 31-Dec-2021 | ||
| WO-2023130028-A1 | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction | Inactive | 31-Dec-2021 | A61K31/50 |
Tenax Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tenax Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tenax Therapeutics Investments & Acquisitions (4)
Tenax Therapeutics’s most recent deal was a Later Stage VC with Tribun Health for . The deal was made on 01-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tribun Health | 01-Dec-2022 | Later Stage VC | Diagnostic Equipment | ||
| PH Precision Med | 15-Jan-2021 | Merger/Acquisition | Drug Discovery | ||
| Phyxius Pharma (Levosimendan Drug) | 14-Nov-2013 | Corporate Asset Purchase | Buildings and Property | ||
| Synthetic Blood International | 30-Jun-2008 | Merger/Acquisition | Drug Discovery |
Tenax Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.54 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tenax Therapeutics FAQs
-
When was Tenax Therapeutics founded?
Tenax Therapeutics was founded in 1967.
-
Where is Tenax Therapeutics headquartered?
Tenax Therapeutics is headquartered in Chapel Hill, NC.
-
What is the size of Tenax Therapeutics?
Tenax Therapeutics has 16 total employees.
-
What industry is Tenax Therapeutics in?
Tenax Therapeutics’s primary industry is Drug Discovery.
-
Is Tenax Therapeutics a private or public company?
Tenax Therapeutics is a Public company.
-
What is Tenax Therapeutics’s stock symbol?
The ticker symbol for Tenax Therapeutics is TENX.
-
What is the current stock price of Tenax Therapeutics?
As of 13-Nov-2026 the stock price of Tenax Therapeutics is $1.62.
-
What is the current market cap of Tenax Therapeutics?
The current market capitalization of Tenax Therapeutics is $73.8M.
-
Who are Tenax Therapeutics’s competitors?
viDA Therapeutics, XyloCor Therapeutics, Immunocore Holdings, Vivus, and Regenerx are some of the 70 competitors of Tenax Therapeutics.
-
What is Tenax Therapeutics’s annual earnings per share (EPS)?
Tenax Therapeutics’s EPS for 12 months was -$1.39.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
